StocksFundsScreenerSectorsWatchlists
XNCR

XNCR - Xencor Inc Stock Price, Fair Value and News

22.27USD-0.15 (-0.67%)Delayed as of 28 Mar 2024, 01:01 pm ET

Market Summary

XNCR
USD22.27-0.15
Delayedas of 28 Mar 2024, 01:01 pm
-0.67%

XNCR Alerts

  • 4 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

XNCR Stock Price

View Fullscreen

XNCR RSI Chart

XNCR Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-11.09

Price/Sales (Trailing)

8.14

EV/EBITDA

-25.73

Price/Free Cashflow

20.56

XNCR Price/Sales (Trailing)

XNCR Profitability

EBT Margin

-48.62%

Return on Equity

-18.47%

Return on Assets

-12.97%

Free Cashflow Yield

4.86%

XNCR Fundamentals

XNCR Revenue

Revenue (TTM)

168.4M

Rev. Growth (Yr)

106.73%

Rev. Growth (Qtr)

-24.5%

XNCR Earnings

Earnings (TTM)

-123.5M

Earnings Growth (Yr)

-160.04%

Earnings Growth (Qtr)

10.8%

Breaking Down XNCR Revenue

52 Week Range

19.2230.21
(Low)(High)

Last 7 days

-2.0%

Last 30 days

-6.3%

Last 90 days

8.0%

Trailing 12 Months

-14.4%

How does XNCR drawdown profile look like?

XNCR Financial Health

Current Ratio

7.36

Debt/Equity

0.02

Debt/Cashflow

5.81

XNCR Investor Care

Shares Dilution (1Y)

1.82%

Diluted EPS (TTM)

-2.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202398.1M113.4M145.3M168.4M
2022326.6M289.4M297.0M164.6M
2021124.3M178.6M162.9M275.1M
202077.1M70.8M84.4M122.7M
2019182.7M172.0M164.7M156.7M
20180078.8M77.8M
201783.8M30.3M29.5M53.2M
201633.5M98.5M102.8M87.5M
20158.8M9.0M11.7M27.8M
201411.0M7.9M5.6M9.5M
20139.7M9.8M10.0M10.2M
20120009.5M

Tracking the Latest Insider Buys and Sells of Xencor Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 11, 2024
eckert celia
sold
-19,976
23.5018
-850
svp, general counsel
Mar 11, 2024
kuch john j
sold
-19,953
23.5018
-849
sr. vice president & cfo
Mar 11, 2024
desjarlais john r
sold
-30,082
23.5018
-1,280
sr. vice president & cso
Mar 11, 2024
dahiyat bassil i
sold
-64,418
23.5018
-2,741
president & ceo
Mar 06, 2024
gustafson kurt a
sold
-324,453
23.1752
-14,000
-
Mar 06, 2024
gustafson kurt a
acquired
160,950
10.73
15,000
-
Mar 05, 2024
desjarlais john r
acquired
-
-
20,724
sr. vice president & cso
Mar 05, 2024
eckert celia
acquired
-
-
13,089
svp, general counsel
Mar 05, 2024
kuch john j
sold
-104,821
23.429
-4,474
sr. vice president & cfo
Mar 05, 2024
dahiyat bassil i
sold
-293,518
23.429
-12,528
president & ceo

1–10 of 50

Which funds bought or sold XNCR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-21.74
-14,165
66,576
-%
Mar 11, 2024
VANGUARD GROUP INC
added
1.74
9,643,730
143,669,000
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
377
14,898,500
18,593,200
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.81
28,984
672,736
-%
Feb 28, 2024
EP Wealth Advisors, LLC
unchanged
-
14,040
275,990
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
20,000
410,000
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
9.38
9,784,000
73,962,000
0.01%
Feb 15, 2024
JANE STREET GROUP, LLC
added
134
530,124
889,580
-%
Feb 15, 2024
NFJ INVESTMENT GROUP, LLC
new
-
1,179,070
1,179,070
0.03%
Feb 15, 2024
Virtus ETF Advisers LLC
added
17.22
17,628
92,626
0.06%

1–10 of 48

Are Funds Buying or Selling XNCR?

Are funds buying XNCR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own XNCR
No. of Funds

Unveiling Xencor Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 16, 2024
t. rowe price investment management, inc.
2.2%
1,351,367
SC 13G/A
Feb 14, 2024
t. rowe price investment management, inc.
2.2%
1,351,367
SC 13G
Feb 14, 2024
ecor1 capital, llc
8.7%
5,282,516
SC 13G/A
Feb 14, 2024
price t rowe associates inc /md/
5.7%
3,489,902
SC 13G/A
Feb 13, 2024
vanguard group inc
11.12%
6,767,249
SC 13G/A
Feb 12, 2024
primecap management co/ca/
14.62%
8,901,607
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 25, 2024
state street corp
5.47%
3,326,856
SC 13G/A
Jan 19, 2024
blackrock inc.
18.6%
11,322,242
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
5.4%
3,218,761
SC 13G/A

Recent SEC filings of Xencor Inc

View All Filings
Date Filed Form Type Document
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 11, 2024
144
Notice of Insider Sale Intent
Mar 11, 2024
144
Notice of Insider Sale Intent
Mar 11, 2024
144
Notice of Insider Sale Intent
Mar 11, 2024
144
Notice of Insider Sale Intent
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading

What is the Fair Value of XNCR?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Xencor Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Xencor Inc News

Latest updates
Simply Wall St • 29 hours ago
Defense World • 22 Mar 2024 • 09:07 am
Seeking Alpha • 28 Feb 2024 • 08:00 am
Seeking Alpha • 28 Feb 2024 • 08:00 am
Yahoo Finance • 19 Feb 2024 • 08:00 am

Xencor Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-24.5%44,670,00059,164,00045,523,00019,000,00021,607,50027,299,00030,175,00085,500,000154,037,00019,683,00067,400,00033,965,00041,854,00035,366,00013,089,00032,385,0003,516,00021,760,00019,485,000111,939,00011,564,000
Operating Expenses2.9%79,698,00077,432,00071,520,00078,327,00064,202,00065,647,00058,175,00059,029,00062,363,50060,983,00058,360,00049,637,00055,552,00052,088,00050,689,00041,162,00034,088,50036,036,00039,057,00033,695,00032,646,500
  S&GA Expenses23.9%15,478,00012,493,00011,460,00013,948,00012,751,00012,374,00011,091,00011,273,00011,375,00010,373,0008,863,0008,226,0007,603,0007,636,0007,231,0007,219,0006,749,5006,266,0005,758,0005,512,0005,517,000
  R&D Expenses-1.1%64,220,00064,939,00060,060,00064,379,00051,451,00053,273,00047,084,00047,756,00050,988,50050,610,00049,497,00041,411,00047,949,00044,452,00043,458,00033,943,00027,339,00029,770,00033,299,00028,183,00027,129,500
EBITDA Margin-254.8%-0.310.20-0.31-0.39-0.250.320.320.280.33-0.38-0.34----------
Interest Expenses38.6%6,954,0005,016,0003,764,0002,892,0002,068,0001,379,000717,000653,000291,000196,000147,000215,000712,0001,423,0002,090,0003,039,0003,418,5003,699,0003,615,0002,886,0002,807,000
Income Taxes-5,811,000----415,0001,088,000-----------288,000-350,00050,000900,000-170,000
Earnings Before Taxes44.6%-13,453,000-24,269,000---12,457,000-31,671,000--73,061,000-40,191,000---13,691,000-12,550,000-35,018,000-8,074,000-27,200,000-10,574,000-15,984,00080,945,000-18,198,000
EBT Margin-1614.5%-0.490.03-0.48-0.56-0.330.280.290.250.30-0.43-0.39----------
Net Income10.8%-21,647,000-24,269,000-20,189,000-57,436,000-8,324,500-32,759,000-35,798,00017,983,00073,105,500-40,191,00052,136,000-2,464,000-13,691,000-12,550,000-34,591,000-8,179,000-26,912,000-10,224,000-16,034,00080,045,000-18,197,000
Net Income Margin3.3%-0.73-0.76-1.05-1.37-0.360.080.050.320.30-0.030.13----------
Free Cashflow698.5%180,226,000-30,113,000-42,053,000-41,397,000-34,397,000-15,253,00031,915,0003,726,00055,470,000-41,768,000-11,937,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets22.4%953778778803846835851858838697696693703646645667670686685697577
  Current Assets9.1%623571594630675668586506424330481591638571603588558574527489316
    Cash Equivalents2.0%54.0053.0035.0072.0054.0053.0049.0078.0014341.0011617716458.0011074.0050.0051.0033.0022.0026.00
  Net PPE-2.8%66.0068.0068.0067.0059.0051.0039.0028.0028.0024.0023.0022.0022.0020.0016.0017.0016.0014.0012.0011.0012.00
Liabilities159.1%28410999.0012011911310995.0010578.0049.0010913178.0074.0074.0077.0076.0077.0087.0055.00
  Current Liabilities59.7%85.0053.0045.0065.0064.0090.0075.0061.0071.0044.0046.0010012170.0066.0066.0067.0064.0064.0073.0054.00
  Long Term Debt-15.00--------------------
    LT Debt, Non Current-15.00--------------------
Shareholder's Equity0.0%669669679684727723742763734619647584572568571593593610608610522
  Retained Earnings-4.3%-464-445-421-399-338-326-293-259-283-356-315-368-365-352-339-304-296-269-259-243-323
  Additional Paid-In Capital1.5%1,1311,1141,1011,0861,0721,0581,0441,0291,018975962951938919908896888878865852845
Shares Outstanding0.5%61.0061.0061.0060.0060.0060.0059.0059.0058.0058.0058.00----------
Minority Interest-0.00--------------------
Float---1,502---1,624---2,000---1,844---2,292--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations764.2%181,206-27,281-38,200-30,614-24,431-1,16844,2695,81561,790-39,023-9,654-29,96617,084-3,866-27,6829,460-19,577-6,477109,156-18,728-16,781
  Share Based Compensation14.0%14,69712,89613,56312,59912,74512,76012,60310,80510,3898,9439,3508,2938,5588,3188,2316,5127,1789,5149,3035,8565,075
Cashflow From Investing-548.2%-203,13045,326-1,40548,14424,5483,125-75,639-71,7597,860-38,848-53,30938,04878,779-50,56059,40812,56515,72722,060-102,43013,6736,866
Cashflow From Financing6355.9%22,9833561,9219221,1711,2872,51373132,6303,2291,8405,3399,5872,9864,0001,4712,9733,0493,9736671,165

XNCR Income Statement

2023-12-31
Consolidated Statements of Income (Loss) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue   
Collaborations, licenses, milestones, and royalties$ 168,338$ 164,579$ 275,111
Operating expenses   
Research and development253,598199,563192,507
General and administrative53,37947,48938,837
Total operating expenses306,977247,052231,344
Income (loss) from operations(138,639)(82,473)43,767
Other income (expense)   
Interest income, net18,6264,817849
Other expense, net(31)(286)(1,274)
Gain (loss) on equity securities, net(395)23,43439,289
Total other income, net18,20027,96538,864
Income (loss) before income tax(120,439)(54,508)82,631
Income tax expense5,8116730
Net income (loss)(126,250)(55,181)82,631
Net loss attributable to non-controlling interest(163)00
Net income (loss) attributable to Xencor, Inc.$ (126,087)$ (55,181)$ 82,631
Net income (loss) per common share attributable to Xencor, Inc.:   
Basic (in dollars per share)$ (2.08)$ (0.93)$ 1.42
Diluted (in dollars per share)$ (2.08)$ (0.93)$ 1.37
Weighted average common shares used to compute net income (loss) per share attributable to Xencor, Inc.   
Basic (in shares)60,503,28359,652,46158,379,641
Diluted (in shares)60,503,28359,652,46160,495,455

XNCR Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 53,790$ 53,942
Marketable debt securities497,725526,689
Marketable equity securities42,21042,431
Accounts receivable11,29028,997
Prepaid expenses and other current assets18,14523,283
Total current assets623,160675,342
Property and equipment, net66,12459,183
Patents, licenses, and other intangible assets, net18,66318,500
Restricted cash3800
Marketable debt securities - long term145,5123,826
Equity securities64,21054,383
Right of use asset33,99534,419
Other assets648613
Total assets952,692846,266
Current liabilities  
Accounts payable13,91410,088
Accrued expenses23,56418,728
Income tax payable5,7820
Lease liabilities3,4354,708
Deferred revenue030,320
Deferred income31,6820
Debt6,3320
Total current liabilities84,70963,844
Lease liabilities, net of current portion59,02554,926
Deferred income, net of current portion125,1830
Debt, net of current portion14,6420
Total liabilities283,559118,770
Commitments and contingencies (see note 9)
Stockholders’ equity  
Preferred stock, $0.01 par value: 10,000,000 authorized shares; -0- issued and outstanding shares at December 31, 2023 and 202200
Common stock, $0.01 par value: 200,000,000 authorized shares; 60,998,191 issued and outstanding shares at December 31, 2023 and 59,997,713 issued and outstanding at December 31, 2022611601
Additional paid-in capital1,131,2661,072,132
Accumulated other comprehensive income1,291(6,952)
Accumulated deficit(464,372)(338,285)
Total stockholders’ equity attributable to Xencor, Inc.668,796727,496
Non-controlling interest3370
Total stockholders' equity669,133727,496
Total liabilities and stockholders’ equity$ 952,692$ 846,266
XNCR
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
 CEO
 WEBSITEwww.xencor.com
 EMPLOYEES281

Xencor Inc Frequently Asked Questions


What is the ticker symbol for Xencor Inc? What does XNCR stand for in stocks?

XNCR is the stock ticker symbol of Xencor Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xencor Inc (XNCR)?

As of Wed Mar 27 2024, market cap of Xencor Inc is 1.37 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XNCR stock?

You can check XNCR's fair value in chart for subscribers.

What is the fair value of XNCR stock?

You can check XNCR's fair value in chart for subscribers. The fair value of Xencor Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xencor Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XNCR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xencor Inc a good stock to buy?

The fair value guage provides a quick view whether XNCR is over valued or under valued. Whether Xencor Inc is cheap or expensive depends on the assumptions which impact Xencor Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XNCR.

What is Xencor Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, XNCR's PE ratio (Price to Earnings) is -11.09 and Price to Sales (PS) ratio is 8.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XNCR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Xencor Inc's stock?

In the past 10 years, Xencor Inc has provided 0.061 (multiply by 100 for percentage) rate of return.